Predicting clinical outcomes in patients with bleeding from gastric cancer: novel tools are needed to nail it!

• References

• 1 Torre LA, Siegel RL, Ward EM. et al. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomarkers Prev 2016; 25: 16-27
• 2 Maluf-Filho F, Martins BC, de Lima MS. et al. Etiology, endoscopic management and mortality of upper gastrointestinal bleeding in patients with cancer. United European Gastroenterol J 2013; 1: 60-67
• 3 Kim YI, Choi IJ, Lee JY. et al. Comparison of the performance of risk scoring systems for tumor bleeding in patients with inoperable gastric cancer. Endoscopy 2020; 52: 359-367
• 4 Barkun AN, Almadi M, Kuipers EJ. et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group. Ann Intern Med 2019;
• 5 Franco MC, Jang S, Martins BC. et al. Comparison of Glagow-Blatchford, Rockall and AIMS65 scores for predicting upper GI bleeding outcomes in patients with cancer. Gastrointest Endosc 2017; 85: AB69-AB70
• 6 Saltzman JR, Tabak YP, Hyett BH. et al. A simple risk score accurately predicts in-hospital mortality, length of stay, and cost in acute upper GI bleeding. Gastrointest Endosc 2011; 74: 1215-1224
• 7 Robertson M, Majumdar A, Boyapati R. et al. Risk stratification in acute upper GI bleeding: comparison of the AIMS65 score with the Glasgow-Blatchford and Rockall scoring systems. Gastrointest Endosc 2016; 83: 1151-1160
• 8 Chen YI, Wyse J, Lu Y. et al. TC-325 hemostatic powder versus current standard of care in managing malignant GI bleeding: a pilot randomized clinical trial. Gastrointest Endosc 2020; 91: 321-328.e1